טוען...
Characterization of in vivo biotransformations for trastuzumab emtansine by high-resolution accurate-mass mass spectrometry
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. T-DM1 is composed of the humanized monoclonal antibody trastuzumab connected to a maytansine derivative cytotoxic drug, via a nonreducible thioether linker at random lysine residues...
שמור ב:
| הוצא לאור ב: | MAbs |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Taylor & Francis
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204834/ https://ncbi.nlm.nih.gov/pubmed/29958059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2018.1494487 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|